|Trade names||Acnestrol, Longestrol|
|Other names||LN-107; α-Bromo-α,β-diphenyl-β-p-ethylphenylethylene; BDPE|
|Drug class||Selective estrogen receptor modulator|
|Chemical and physical data|
|Molar mass||363.290 g/mol g·mol−1|
|3D model (JSmol)|
Broparestrol (INN) (brand names Acnestrol, Longestrol; former developmental code name LN-107), also known as α-bromo-α,β-diphenyl-β-p-ethylphenylethylene (BDPE), is a synthetic, nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that has been used in Europe as a dermatological agent and for the treatment of breast cancer. The drug is described as slightly estrogenic and potently antiestrogenic, and inhibits mammary gland development and suppresses prolactin levels in animals. It is structurally related to clomifene and diethylstilbestrol. Broparestrol is a mixture of E- and Z- isomers (LN-1643 and LN-2299, respectively), both of which are active and are similarly antiestrogenic but, unlike broparestrol, were never marketed.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|